Wealth Architects Lowers stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Wealth Architects reduced its stake in Merck & Co. by 1.54% during the most recent quarter end. The investment management company now holds a total of 11,347 shares of Merck & Co. which is valued at $611,376 after selling 177 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on May 12, 2016.Merck & Co. makes up approximately 0.31% of Wealth Architects’s portfolio.

Other Hedge Funds, Including , Carnick Kubik reduced its stake in MRK by selling 455 shares or 3.56% in the most recent quarter. The Hedge Fund company now holds 12,333 shares of MRK which is valued at $664,502. Merck & Co. makes up approx 0.33% of Carnick Kubik’s portfolio.Hallmark Capital Management Inc boosted its stake in MRK in the latest quarter, The investment management firm added 8,248 additional shares and now holds a total of 29,349 shares of Merck & Co. which is valued at $1.6 Million. Merck & Co. makes up approx 0.26% of Hallmark Capital Management Inc’s portfolio.California Public Employees Retirement System boosted its stake in MRK in the latest quarter, The investment management firm added 33,699 additional shares and now holds a total of 7,831,053 shares of Merck & Co. which is valued at $419.7 Million. Merck & Co. makes up approx 0.66% of California Public Employees Retirement System’s portfolio.Cadence Bank Na boosted its stake in MRK in the latest quarter, The investment management firm added 302 additional shares and now holds a total of 80,899 shares of Merck & Co. which is valued at $4.3 Million. Merck & Co. makes up approx 2.23% of Cadence Bank Na’s portfolio.Aperio Group boosted its stake in MRK in the latest quarter, The investment management firm added 116,425 additional shares and now holds a total of 1,333,304 shares of Merck & Co. which is valued at $73.1 Million. Merck & Co. makes up approx 0.62% of Aperio Group’s portfolio.

Merck & Co. opened for trading at $54.83 and hit $55.54 on the upside on Friday, eventually ending the session at $55.11, with a gain of 0.97% or 0.53 points. The heightened volatility saw the trading volume jump to 86,33,110 shares. Company has a market cap of $152,546 M.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.